1-3 of 3
Sagar Agarwal
Close
Sort by
Journal Articles

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Aditi Shastri, Eric J Feldman, Alexander N Starodub, Tatyana Feldman, Cristina P Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J Olszewski, Auris O Huen, Pierluigi Porcu, John C Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, Stephen D Smith
Journal: Blood
Blood (2023) 142 (Supplement 1): 3081.
https://doi.org/10.1182/blood-2023-181130
Published: 2023
Journal Articles

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Jennifer Kimberly Lue, Don A. Stevens, Michael E. Williams, Jason Westin, Reggie Ewesuedo, Alice McDonald, Sagar Agarwal, Patrick Henrick, Rachelle Perea, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12143–12144.
https://doi.org/10.1182/blood-2022-170151
Published: 2022
Journal Articles

A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Stephen D Smith, Alexander Starodub, Don A. Stevens, Aditi Shastri, Pierluigi Porcu, Tatyana Feldman, Reggie Ewesuedo, Chris DeSavi, Joyoti Dey, Sagar Agarwal, Sean Donohue, Rachelle Perea, Christine Klaus, Jared Gollob
Journal: Blood
Blood (2022) 140 (Supplement 1): 12024–12025.
https://doi.org/10.1182/blood-2022-169514
Published: 2022